Last updated on August 2018

Safety and Exploratory Efficacy Study of NEUROSTEM Versus Placebo in Patients With Alzheimer's Disease

Brief description of study

This combined phase 1/2a clinical trial is to investigate the safety, dose limiting toxicity (DLT), and exploratory efficacy of three repeated intraventricular administrations of NEUROSTEM (human umbilical cord blood-derived mesenchymal stem cells) versus placebo via an Ommaya reservoir at 4 week intervals in patients with Alzheimer's disease.

Detailed Study Description

The study is divided into the 2 stages: dose-escalation in stage 1 and randomized and multiple-dose cohort parallel design in stage 2.The target population for enrollment in this study is patients with mild to moderate Alzheimer's disease.

Clinical Study Identifier: NCT02054208

Contact Investigators or Research Sites near you

Start Over

Duk L. Na, MD

Samsung Medical Center
Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.